KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

RTTNews | 911 days ago
Stocktwits
KalVista Pharma Terminates KVD824 Phase 2 KOMPLETE Trial For Prophylactic Treatment Of HAE

(RTTNews) - KalVista Pharmaceuticals, Inc. (KALV) announced Monday that it has terminated the KOMPLETE phase 2 clinical trial for KVD824 for the prevention of attacks in people with hereditary angioedema (HAE).

This decision was based on the observation of liver enzyme (ALT/AST) elevations in multiple patients in all treatment groups of the trial. No patients had concomitant elevation of bilirubin levels and all were asymptomatic.

The KOMPLETE trial is a phase 2 clinical trial evaluating KVD824, an investigational oral plasma kallikrein inhibitor designed for the prevention of attacks in adults living with HAE.

Patients in the trial were randomized to one of three treatment groups, each placebo controlled: 300 mg, 600 mg, 900 mg KVD824 (or placebo), all dosed twice daily.

KalVista continues to recruit the phase 3 KONFIDENT trial assessing sebetralstat (formerly KVD900) as a potential oral, on-demand therapy for HAE attacks, with data anticipated in the second half of 2023.

For More Such Health News, visit rttnews.com

Tags: KALV
Stocktwits
read more
KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharma Appoints Brian Piekos As New CFO

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector.
RTTNews | 204 days ago
European Economic News Preview: Eurozone Final Composite PMI Data Due

European Economic News Preview: Eurozone Final Composite PMI Data Due

Final composite Purchasing Managers' survey results from the euro area and the UK are the top economic news due at Thursday. At 3.15 AM ET, S&P Global publishes Spain's services and composite PMI survey data. The services indicator is forecast to fall to 55.6 in March from 56.2 in the previous month. At 3.45 am ET, services and composite PMI data is due from Italy.
RTTNews | 4h 15min ago
Sensex, Nifty Open Lower; IT And Auto Stocks Drag

Sensex, Nifty Open Lower; IT And Auto Stocks Drag

Indian shares were slightly lower on Thursday after U.S. President Donald Trump announced 26 percent reciprocal tariff on India - half the rate India imposes on U.S. imports, leaving some room for negotiation.
RTTNews | 5h 27min ago
Asian Markets Trades Mostly Lower

Asian Markets Trades Mostly Lower

Asian stock markets are trading mostly lower on Thursday, despite the positive cues from Wall Street overnight, after US President Donald Trump announced steeper-than-expected tariffs on US trade partners, heightening concerns over a global trade war that could destabilize major economies. White House press secretary Karoline Leavitt indicated the new levies will be "effective immediately."
RTTNews | 6h 18min ago
Australian Market Trims Early Losses In Mid-market

Australian Market Trims Early Losses In Mid-market

The Australian market is trimming its early losses in mid-market moves on Thursday, giving up the gains in the previous two sessions, despite the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling well below the 7,900 level, with weakness across most sectors led by mining and technology stocks.
RTTNews | 7h 6min ago
Sensex, Nifty Likely To See Gap-down Open As Trade War Fears Mount

Sensex, Nifty Likely To See Gap-down Open As Trade War Fears Mount

Indian shares look set to open sharply lower on Thursday after U.S. President Donald Trump announced reciprocal tariffs affecting over 180 countries, including a 26 percent tariff on India - half the rate India imposes on U.S. imports, leaving some room for negotiation.
RTTNews | 7h 16min ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading Courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Press Release
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2025 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.